Naphazoline Shortage: What Providers and Prescribers Need to Know in 2026

Patients may come to you confused about naphazoline availability — they've heard it's been discontinued and may be asking whether they should switch to something else. This clinical overview covers what providers need to know about the current status of naphazoline products in 2026, clinical implications, and evidence-based recommendations for alternatives when appropriate.

Current Regulatory and Market Status

Naphazoline hydrochloride as a standalone OTC product has been voluntarily discontinued by manufacturers in the United States. The FDA has confirmed this was not a safety-related withdrawal. There is no active FDA drug shortage designation for naphazoline or its combination products as of 2026.

Naphazoline remains widely available as an active ingredient in the following FDA-approved OTC formulations:

Naphazoline HCl 0.012%–0.027% + glycerin (lubricant/redness reliever) — e.g., Clear Eyes Redness Relief

Naphazoline HCl 0.025%–0.027% + pheniramine maleate 0.3% (antihistamine/decongestant) — e.g., Naphcon-A, Opcon-A, Visine-A

Naphazoline + zinc sulfate (astringent/redness reliever) — e.g., Clear Eyes ACR, VasoClear A

Naphazoline HCl 0.05% nasal drops — available OTC for temporary nasal decongestant use

Pharmacology Reminder: Mechanism and Limitations

Naphazoline is a mixed alpha-1 and alpha-2 adrenergic receptor agonist. Its ophthalmic effect is mediated through alpha-receptor stimulation in the conjunctival vasculature, producing vasoconstriction and rapid, cosmetic reduction of redness. Onset is within 10 minutes, duration 3–4 hours for the 0.1% formulation.

Key clinical limitations to communicate to patients:

Conjunctivitis medicamentosa (rebound hyperemia): Chronic use beyond the labeled 72-hour period causes tachyphylaxis and rebound redness. Patients with chronic red eye from naphazoline overuse require a gradual taper or substitution.

No anti-inflammatory or antiallergic effect: Naphazoline does not treat allergic conjunctivitis — it only masks the redness. Patients with allergic etiology should be directed to antihistamine/mast cell stabilizer products.

Narrow-angle glaucoma contraindication: Mydriasis from naphazoline can precipitate acute angle-closure in susceptible patients. Contraindicated in angle-closure glaucoma.

MAO inhibitor interaction: Concurrent use with MAO inhibitors (phenelzine, tranylcypromine, selegiline) may cause severe hypertensive crisis due to potentiation of sympathomimetic effects.

Pediatric toxicity risk: Accidental ingestion in infants or young children can cause serious adverse events including CNS depression, coma, hypothermia, bradycardia, and hypotension. Advise parents accordingly.

Evidence-Based Alternatives to Recommend

For patients who can no longer find standalone naphazoline or who need a better long-term option, consider these evidence-based alternatives:

Brimonidine 0.025% (Lumify): Selective alpha-2 agonist; reduced rebound hyperemia compared to non-selective alpha agonists; OTC; appropriate for short-term cosmetic redness relief

Ketotifen 0.025%–0.035% (Alaway, Zaditor): H1-antihistamine and mast cell stabilizer; OTC; first-line for mild-to-moderate allergic conjunctivitis; no rebound risk; appropriate for ages 3+ (Zaditor) or 3+ (Alaway)

Olopatadine 0.1%–0.7% (Pataday, Pazeo): Dual-action H1-antagonist/mast cell stabilizer; OTC (0.2%) and Rx (0.7%); superior efficacy over naphazoline/pheniramine in allergic conjunctivitis trials; once-daily dosing improves adherence

Alcaftadine 0.25% (Lastacaft): Rx antihistamine with once-daily dosing; effective for prevention of allergic conjunctivitis symptoms

Counseling Patients on Naphazoline Combination Products

If patients still want naphazoline-containing products, counsel them on the following:

Search for brand-name products (Clear Eyes, Naphcon-A, Visine-A), not generic "naphazoline"

Limit use to 72 hours per episode; do not use continuously

If they have glaucoma, confirm open-angle status before recommending any vasoconstrictor

Remove contact lenses before use and wait at least 15 minutes before reinserting

Keep products locked away from young children; accidental ingestion can be life-threatening in infants

How medfinder Supports Your Patients

When patients are having difficulty locating a specific medication at their pharmacy, medfinder for providers offers a referral solution. medfinder calls pharmacies on your patient's behalf to find which ones have the medication in stock, then texts the patient the results. This reduces unnecessary callbacks, patient frustration, and prescription abandonment. medfinder covers all medications, including OTC products.

For more on the provider workflow, see our provider's guide to helping patients find naphazoline in stock.